Bentley Pharma (BNT) Announces Adjustment To Teva (TEVA) Merger Price
More News related to BNT
- Notable Mergers and Acquisitions of the Day 7/23 (CSCO, BNT/TEVA, PHLY)
- Bentley (BNT) Shareholders Approve Merger with TEVA Pharma (TEVA)
- Bentley Pharma (BNT) Announces Adjustment To Teva (TEVA) Merger Price
- Bentley Pharmaceuticals (BNT) Misses Q1 EPS Views
- Unusual 11 Mid-Day Movers 3/31: ANST, VRTX, BNT, XJT Higher; SGP, FRP, TMA, MRK Lower
More News related to CPEX
- CPEX's Nasulin Insulin Therapy Featured in an Oral Presentation and Four Abstracts at the Ninth Annual Diabetes Technology Meeting
- CPEX Pharmaceuticals Reports Third-Quarter 2009 Financial Results
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
- StockPreacher.com Issues Trading Outlook for Novadel Pharma Inc.
- CPEX Pharmaceuticals to Present at Ninth Annual Diabetes Technology Meeting
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Mergers and Acquisitions
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
Bentley Pharmaceuticals, Inc. (NYSE: BNT) said the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX).
Bentley stockholders will receive from Teva a final per-share purchase price of approximately $14.82 in cash in exchange for their Bentley common stock if the merger agreement is approved by Bentley’s stockholders and the other closing conditions are satisfied or waived in accordance with the merger agreement.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
